DOAC-Remove tablets are intended for removal of Direct Oral Anticoagulant (DOAC) compounds from human citrated plasma samples, including dabigatran, rivaroxaban, apixaban, edoxaban, and argatroban. One tablet neutralizes the influence of DOACs in 1 mL (range 0.5 to 2 mL) citrated plasma sample. DOAC-Remove reduces false positivity for lupus anticoagulants and eliminates interference on routine coagulation assays such as APTT, PT, TT, single factors, chromogenic assays, and APC-R. After incubation and centrifugation, the plasma supernatant can immediately be used for hemostasis assays or frozen for later use. No significant effect on clotting factors has been reported. 5-year shelf life.

For Research Use Only.